@article{97f0e79d435d421f9029c39edff1bddf,
title = "Aducanumab: look before leaping",
author = "Perlmutter, {Joel S.}",
note = "Funding Information: J.P. has received research funding from the US National Institutes of Health, the US Department of Defense, the Michael J Fox Foundation, the Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson disease research fund), the American Parkinson Disease Association Advanced Research Center at Washington University, the Greater St. Louis Chapter of the American Parkinson Disease Association, the Paula and Rodger Riney Fund, the Jo Oertli Fund, the Huntington Disease Society of America, the Murphy Fund and CHDI. J.P. has received honoraria from CHDI, the Huntington Disease Study Group, the Parkinson Study Group, Beth Israel Hospital (Harvard group), the University of Pennsylvania, Stanford University and Boston University. J.P. has provided medical legal consultation to Wood, Cooper and Peterson, LLC, and to Simmons and Simmons, LLP. J.P. was a member of the Peripheral and Central Nervous System Drugs Advisory Committee of the FDA but resigned on 7 June 2021, and participated in the advisory committee meeting of 6 November 2020.",
year = "2021",
month = sep,
doi = "10.1038/s41591-021-01477-5",
language = "English",
volume = "27",
pages = "1499",
journal = "Nature medicine",
issn = "1078-8956",
number = "9",
}